We report a case of breakthrough invasive zygomycosis in a stem cell transplant recipient who was receiving caspofungin for treatment of a breakthrough Candida krusei fungemia that occurred during fluconazole prophylaxis. Also, patients receiving the echinocandin caspofungin remain at risk for pathogens, such as zygomycetes, that are intrinsically resistant to this agent.
Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomicosis during caspofungin therapy in a patients with severe aplastic anemia who underwent stem cell transplantation / Girmenia, C; Moleti, Ml; Micozzi, Alessandra; Iori, Ap; Barberi, Walter; Foa, Roberto; Martino, P.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - 43 (10):(2005), pp. 5395-5396. [10.1128/JCM.43.10.5395-5396.2005]
Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomicosis during caspofungin therapy in a patients with severe aplastic anemia who underwent stem cell transplantation
MICOZZI, Alessandra;BARBERI, Walter;FOA, Roberto;
2005
Abstract
We report a case of breakthrough invasive zygomycosis in a stem cell transplant recipient who was receiving caspofungin for treatment of a breakthrough Candida krusei fungemia that occurred during fluconazole prophylaxis. Also, patients receiving the echinocandin caspofungin remain at risk for pathogens, such as zygomycetes, that are intrinsically resistant to this agent.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
